Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Intangibles (2016 - 2025)

Historic Intangibles for Aytu Biopharma (AYTU) over the last 11 years, with Q4 2025 value amounting to $58.4 million.

  • Aytu Biopharma's Intangibles fell 1828.51% to $58.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $58.4 million, marking a year-over-year decrease of 1828.51%. This contributed to the annual value of $55.4 million for FY2025, which is 2248.28% down from last year.
  • Aytu Biopharma's Intangibles amounted to $58.4 million in Q4 2025, which was down 1828.51% from $55.4 million recorded in Q3 2025.
  • In the past 5 years, Aytu Biopharma's Intangibles registered a high of $114.6 million during Q1 2021, and its lowest value of $55.4 million during Q2 2025.
  • For the 5-year period, Aytu Biopharma's Intangibles averaged around $81.1 million, with its median value being $78.6 million (2023).
  • As far as peak fluctuations go, Aytu Biopharma's Intangibles soared by 9285.64% in 2021, and later crashed by 2248.28% in 2025.
  • Quarter analysis of 5 years shows Aytu Biopharma's Intangibles stood at $94.2 million in 2021, then decreased by 4.95% to $89.6 million in 2022, then decreased by 13.04% to $77.9 million in 2023, then decreased by 8.23% to $71.5 million in 2024, then dropped by 18.29% to $58.4 million in 2025.
  • Its Intangibles stands at $58.4 million for Q4 2025, versus $55.4 million for Q3 2025 and $55.4 million for Q2 2025.